NCT04176380: RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma |
|
|
| Recruiting | 2 | 27 | US | RAPA-201 Autologous T cells, RAPA-201 cells | Rapa Therapeutics LLC, Medical College of Wisconsin | Relapsed, Refractory Multiple Myeloma | 10/23 | 10/23 | | |
NCT06708455: Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma |
|
|
| Not yet recruiting | 2 | 65 | US | RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy | Rapa Therapeutics LLC | Malignant Melanoma with Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV | 03/28 | 09/28 | | |
| Recruiting | 1/2 | 22 | US | RAPA-201 Rapamycin Resistant T Cells, RAPA-201 cells, Chemotherapy Prior to RAPA-201 Therapy | Rapa Therapeutics LLC | Solid Tumor, Breast Cancer, Small Cell and Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Gastric Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Carcinoma of Unknown Primary, Bladder Cancer, Malignant Melanoma | 01/24 | 12/24 | | |
